摘要:
Compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein : R 1 and R 2 are independently C 1-4 alkyl; or R 1 and R 2 together with the nitrogen atom to which they are joined represent a pyrrolidino, piperidino or hexahydroazepino ring; Y is straight-chain or branched-chain C 1-4 alkyl; n is 2 to 5; m is 0 or 1; when m is 1, Z is inter alia an optionally substituted pyridine, pyrimidine, oxazole, thiazole, imidazole, benzoxazole benzthiazole or N-alkylbenzimidazole ring; when m is 0, Z is an optionally substituted imidazole, pyrazole or benzimidazole ring. The compounds are histamine H 2 -receptors antagonists and relatively lipophilic and can penetrate the blood-brain barrier and are useful in treating diseases mediated via histamine H 2 -receptors. Processes for their preparation, pharmaceutical compositions and methods of use are described.
摘要:
Die Erfindung betrifft ein Verfahren zur Herstellung von 5(6)-Thiocyano-benzimidazol-Derivaten der Formel (R = H, Halogen, C 1-4 -Alkyl, C 1-3 -Alkoxy oder Trifluormethyl, R 1 = Amino oder C 1-4 -Alkoxycarbonylamino) sowie deren Salzen, durch Umsetzung von Benzimidazol-Derivaten der Formel mit Chlorgas und einem Alkali-, Erdalkali- oder Ammoniumrhodanid. I sind Zwischenprodukte für die Herstellung von Anthelmintica.
摘要:
Novel benzimidazole derivatives of the formula: wherein R' is an alkyl group having 1 to 3 carbon atoms, allyl group, propargyl group, or phenyl group; R 2 is hydrogen atom or an alkyl group having 1 to 3 carbon atoms; and n is 2 or 3, or pharmaceutically acceptable acid addition salts thereof, which have excellent antihistaminic activities and are useful as antiallergics for various allergic diseases, and a process for the preparation thereof, and an antihistaminic composition containing the compound as an active ingredient.
摘要:
Intranasal formulations for antiviral benzimidazole compounds are disclosed. The formulations contain the active ingredient; a non-ionic, surface-active agent with a HLB number from 12 to 16; and a propellant.
摘要:
Intranasal formulations for antiviral benzimidazole compounds are disclosed. The formulations contain the active ingredient; a non-ionic, surface-active agent with a HLB number from 12 to 16; and a propellant.
摘要:
To separate the syn and anti oximes of the formula wherein R 1 is C 1 -C 5 alkyl; and R 2 is phenyl, or phenyl substituted by C 1 -C 4 alkyl, C 1 -C 4 alkoxy, chloro, bromo, iodo, nitro or trifluoromethyl, e.g. 1-isopropylsulfonyl-2-amino-6-(a-hydroximinobenzyl)-benzimidazole, a mixture of these oximes is dissolved in a water miscible organic solvent selected from methyl ethyl ketone, methanol, ethanol, isopropanol, acetonitrile, dimethylacetamide, dimethyl sulfoxide and, preferably, acetone, a sufficient quantity of water is added to initiate crystallization, and the precipitated anti oxime isomer which displays good antiviral activity is separated, e.g. in greater than about 95% purity.